Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Page 1
Final five-year results of the REMEDEE Registry: Real-world experience with the dual-therapy COMBO stent.
Kerkmeijer LSM, Chandrasekhar J, Kalkman DN, Woudstra P, Menown IBA, Suryapranata H, den Heijer P, Iñiguez A, van 't Hof AWJ, Erglis A, Arkenbout KE, Muller P, Koch KT, Tijssen JG, Beijk MAM, de Winter RJ. Kerkmeijer LSM, et al. Among authors: woudstra p. Catheter Cardiovasc Interv. 2021 Sep;98(3):503-510. doi: 10.1002/ccd.29305. Epub 2020 Oct 8. Catheter Cardiovasc Interv. 2021. PMID: 33029937 Free PMC article.
OBJECTIVES: This final report from the REMEDEE Registry assessed the long-term safety and efficacy of the dual-therapy COMBO stent in a large unselected patient population. BACKGROUND: The bio-engineered COMBO stent (OrbusNeich Medical BV, The Netherlands) is a dual-therap …
OBJECTIVES: This final report from the REMEDEE Registry assessed the long-term safety and efficacy of the dual-therapy COMBO stent in …
1-Year Clinical Outcomes of All Comers Treated With 2 Bioresorbable Polymer-Coated Sirolimus-Eluting Stents: Propensity Score-Matched Comparison of the COMBO and Ultrathin-Strut Orsiro Stents.
Chandrasekhar J, Kok MM, Kalkman DN, Aquino MB, Zocca P, Woudstra P, Beijk MA, Kerkmeijer LS, Sartori S, Baber U, Tijssen JG, Koch KT, Dangas GD, Colombo A, Pocock S, von Birgelen C, Mehran R, de Winter RJ; COMBO Collaborators and BIO-RESORT Investigators. Chandrasekhar J, et al. Among authors: woudstra p. JACC Cardiovasc Interv. 2020 Apr 13;13(7):820-830. doi: 10.1016/j.jcin.2019.11.023. JACC Cardiovasc Interv. 2020. PMID: 32273094 Free article.
(Comparison of Biodegradable Polymer and Durable Polymer Drug-Eluting Stents in an All Comers Population [BIO-RESORT], NCT01674803; MASCOT-Post Marketing Registry [MASCOT], NCT02183454; Prospective Registry to Assess the Long-term Safety and Performance of the Combo Stent …
(Comparison of Biodegradable Polymer and Durable Polymer Drug-Eluting Stents in an All Comers Population [BIO-RESORT], NCT01674803; MASCOT-P …
Long-Term Performance of the COMBO Dual-Therapy Stent: Results from the REMEDEE Registry.
Kerkmeijer LS, Kalkman DN, Woudstra P, Menown IBA, Suryapranata H, den Heijer P, Iñiguez A, Van't Hof AWJ, Erglis A, Arkenbout KE, Muller P, Koch KT, Tijssen JG, Beijk MAM, de Winter RJ. Kerkmeijer LS, et al. Among authors: woudstra p. Cardiovasc Revasc Med. 2020 May;21(5):567-570. doi: 10.1016/j.carrev.2019.09.015. Epub 2019 Oct 25. Cardiovasc Revasc Med. 2020. PMID: 31662276
BACKGROUND: Data of long-term safety and efficacy of the COMBO dual-therapy stent is lacking. ...
BACKGROUND: Data of long-term safety and efficacy of the COMBO dual-therapy stent is lacking. ...
1-Year Clinical Outcomes of All-Comer Patients Treated With the Dual-Therapy COMBO Stent: Primary Results of the COMBO Collaboration.
de Winter RJ, Chandrasekhar J, Kalkman DN, Aquino MB, Woudstra P, Beijk MA, Sartori S, Baber U, Tijssen JG, Koch KT, Dangas GD, Colombo A, Mehran R; MASCOT; REMEDEE Registry Investigators. de Winter RJ, et al. Among authors: woudstra p. JACC Cardiovasc Interv. 2018 Oct 8;11(19):1969-1978. doi: 10.1016/j.jcin.2018.04.038. JACC Cardiovasc Interv. 2018. PMID: 30286855 Free article. Clinical Trial.
(MASCOT - Post Marketing Registry [MASCOT]; NCT02183454; Prospective Registry to Assess the Long-term Safety and Performance of the COMBO Stent [REMEDEE Reg]; NCT01874002)....
(MASCOT - Post Marketing Registry [MASCOT]; NCT02183454; Prospective Registry to Assess the Long-term Safety and Performance of the C …
Five-year clinical follow-up of the STENTYS self-apposing stent in complex coronary anatomy: a single-centre experience with report of specific angiographic indications.
Lu H, Bekker RJ, Grundeken MJ, Woudstra P, Wykrzykowska JJ, Tijssen JGP, de Winter RJ, Koch KT. Lu H, et al. Among authors: woudstra p. Neth Heart J. 2018 May;26(5):263-271. doi: 10.1007/s12471-018-1111-7. Neth Heart J. 2018. PMID: 29654515 Free PMC article.
OBJECTIVES: We sought to investigate angiographic indications for the use of the STENTYS technique and evaluated the long-term safety and clinical efficacy of the stent. BACKGROUND: Coronary lesions involving complex anatomy, including aneurysmatic, ectatic, or tapered ves …
OBJECTIVES: We sought to investigate angiographic indications for the use of the STENTYS technique and evaluated the long-term safety …
Five-year follow-up of the endothelial progenitor cell capturing stent versus the paxlitaxel-eluting stent in de novo coronary lesions with a high risk of coronary restenosis.
Woudstra P, Kalkman DN, Beijk MA, Klomp M, Damman P, Koch KT, Henriques JPS, Baan J Jr, Vis MM, Piek JJ, Tijssen JGP, de Winter RJ. Woudstra P, et al. Catheter Cardiovasc Interv. 2018 Jun;91(7):1212-1218. doi: 10.1002/ccd.27249. Epub 2017 Sep 4. Catheter Cardiovasc Interv. 2018. PMID: 28868810 Clinical Trial.
OBJECTIVES: To assess the long-term safety and clinical efficacy of the Genous endothelial progenitor cell capturing stent (ECS) compared with the TAXUS Liberte paclitaxel-eluting stent (PES) in lesions with a high risk of restenosis. ...CONCLUSION: This is the first rando …
OBJECTIVES: To assess the long-term safety and clinical efficacy of the Genous endothelial progenitor cell capturing stent (ECS) comp …
Early Invasive Versus Selective Strategy for Non-ST-Segment Elevation Acute Coronary Syndrome: The ICTUS Trial.
Hoedemaker NPG, Damman P, Woudstra P, Hirsch A, Windhausen F, Tijssen JGP, de Winter RJ; ICTUS Investigators. Hoedemaker NPG, et al. Among authors: woudstra p. J Am Coll Cardiol. 2017 Apr 18;69(15):1883-1893. doi: 10.1016/j.jacc.2017.02.023. J Am Coll Cardiol. 2017. PMID: 28408018 Free article. Clinical Trial.
BACKGROUND: The ICTUS (Invasive Versus Conservative Treatment in Unstable Coronary Syndromes) trial compared early invasive strategy with a selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) and an elevated cardiac troponin T. …
BACKGROUND: The ICTUS (Invasive Versus Conservative Treatment in Unstable Coronary Syndromes) trial compared early invasive strategy with a …
1-Year Results of the REMEDEE Registry: Clinical Outcomes After Deployment of the Abluminal Sirolimus-Coated Bioengineered (Combo) Stent in a Multicenter, Prospective All-Comers Registry.
Woudstra P, Kalkman DN, den Heijer P, Menown IB, Erglis A, Suryapranata H, Arkenbout KE, Iñiguez A, van 't Hof AW, Muller P, Tijssen JG, de Winter RJ. Woudstra P, et al. JACC Cardiovasc Interv. 2016 Jun 13;9(11):1127-34. doi: 10.1016/j.jcin.2016.02.052. Epub 2016 May 18. JACC Cardiovasc Interv. 2016. PMID: 27209254 Free article. Clinical Trial.
CONCLUSIONS: This registry showed excellent 1-year results of novel Combo bioengineered stent technology in an all-comers patient population. (Prospective Registry to Assess the Long-term Safety and Performance of the Combo Stent [REMEDEE]; NCT01874002)....
CONCLUSIONS: This registry showed excellent 1-year results of novel Combo bioengineered stent technology in an all-comers patient population …
Long-term mortality after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in patients with insulin-treated versus non-insulin-treated diabetes mellitus.
Hoebers LP, Claessen BE, Woudstra P, DeVries JH, Wykrzykowska JJ, Vis MM, Baan J Jr, Koch KT, Tijssen JG, de Winter RJ, Piek JJ, Henriques JP. Hoebers LP, et al. Among authors: woudstra p. EuroIntervention. 2014 May;10(1):90-6. doi: 10.4244/EIJV10I1A15. EuroIntervention. 2014. PMID: 24832639 Free article.
AIMS: We investigated the impact of preadmission diabetic status on long-term outcome in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI), to improve risk stratification. ...After adjustment for …
AIMS: We investigated the impact of preadmission diabetic status on long-term outcome in patients with ST-segment elevation myocardia …
Admission lipoprotein-associated phospholipase A2 activity is not associated with long-term clinical outcomes after ST-segment elevation myocardial infarction.
Woudstra P, Damman P, Kuijt WJ, Kikkert WJ, Grundeken MJ, van Brussel PM, Stroobants AK, van Straalen JP, Fischer JC, Koch KT, Henriques JP, Piek JJ, Tijssen JG, de Winter RJ. Woudstra P, et al. PLoS One. 2014 May 1;9(5):e96251. doi: 10.1371/journal.pone.0096251. eCollection 2014. PLoS One. 2014. PMID: 24788873 Free PMC article.
However, the prognostic value in patients undergoing primary percutaneous coronary intervention (pPCI) for ST-segment elevation myocardial infarction (STEMI) on long-term clinical outcomes is unknown. METHODS: Lp-PLA2 activity was measured in samples obtained prior to pPCI …
However, the prognostic value in patients undergoing primary percutaneous coronary intervention (pPCI) for ST-segment elevation myocardial i …
18 results